Knowledge, Attitude, and Acceptance of Sinopharm and AstraZeneca's COVID-19 Vaccines among Egyptian Population: A Cross-Sectional Study

Int J Environ Res Public Health. 2022 Dec 14;19(24):16803. doi: 10.3390/ijerph192416803.

Abstract

Background: This study aimed to evaluate the Egyptian population's preference and awareness related to available COVID-19 vaccines and to determine different factors that can affect beliefs concerning these vaccines.

Methods: A cross-sectional web-based study was carried out among the general population in Egypt. Data collection was conducted via an online questionnaire.

Results: About 426 subjects participated in the survey. Vaccine preference is nearly equally even (50%) among all respondents. There was no significant difference in vaccine preference according to age, gender, residence, educational level, or social status. About 50% of public respondents mentioned that both AstraZeneca and Sinopharm vaccines do not offer protection against new variant COVID-19 strains. Healthcare workers are the lowest respondents to agree that vaccines offer protection against new COVID-19 variants (10.9%) compared to unemployed respondents (20.3%) and other professions (68.8%) with a statistically significant difference (p < 0.005). Safety of vaccine administration among children below 18 showed statistical differences for gender and educational level predictors.

Conclusions: Most of the study population has satisfying knowledge about the COVID-19 vaccine. Continuous awareness campaigns must be carried out so that the people's background is updated with any new information that would help in raising the trust in vaccination.

Keywords: AstraZeneca; COVID-19; Sinopharm; awareness; vaccines.

MeSH terms

  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Child
  • Cross-Sectional Studies
  • Egypt / epidemiology
  • Health Knowledge, Attitudes, Practice
  • Humans
  • SARS-CoV-2
  • Vaccination
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This research received no external funding.